Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease of unknown cause. The pathogenesis of SSc is characterized by microvascular fibroproliferative vasculopathy and immune dysregulation that promote excessive collagen and extracellular matrix deposition. Although many disease-modifying agents have been used to treat internal organ involvement, these medications often have modest efficacy on the cutaneous manifestations of SSc, including progressive facial dermal sclerosis.1 Microstomia, or limited mouth opening, is a common and debilitating cutaneous manifestation of SSc resulting in difficulty with mastication, phonation, and oral hygiene. Of note, a study of 300 patients with SSc found that facial involvement and microstomia were patients’ greatest concerns.2
Melvin OG, Hunt KM, Jacobson ES. Hyaluronidase Treatment of Scleroderma-Induced Microstomia. JAMA Dermatol. Published online May 29, 2019. doi:10.1001/jamadermatol.2019.0585
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: